Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence to develop transformative neuroscience and immuno-oncology medicines. Its core business involves repurposing existing drugs using AI-driven platforms to identify new therapeutic indications, focusing on neuropsychiatric disorders and cancer. Key products include IGALMI®, an FDA-approved sublingual film for agitation in schizophrenia and bipolar disorder, and investigational candidates like BXCL501. The company targets patients with unmet medical needs through clinical development and potential partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.